Euroopa Liit - eesti - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muud närvisüsteemi ravimid - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Eesti - eesti - Ravimiamet

aktsiaselts elme messer gaas - dilämmastikoksiid+hapnik - meditsiiniline surugaas - 50%+50% 2l 1tk; 50%+50% 15l 1tk; 50%+50% 10l 1tk; 50%+50% 5l 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant võib kasutada monoteraapiana või kombinatsioonis metotreksaadiga. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Eesti - eesti - Ravimiamet

stada arzneimittel ag - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 56tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 14tk; 240mg 180tk; 240mg 28tk

Eesti - eesti - Ravimiamet

norameda uab - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 14tk

Eesti - eesti - Ravimiamet

norameda uab - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 56tk

Eesti - eesti - Ravimiamet

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 100tk; 120mg 14tk

Eesti - eesti - Ravimiamet

teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 168tk